ArticleIranian journal of basic medical sciences2026
Efficacy of finerenone and/or roflumilast in alleviation of intestinal ischemic reperfusion injury via regulation of IL10/AMPK/VEGF/eNOS pathway in rats.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Intestinal ischemia is a serious emergency that requires immediate management and surgical intervention. Finding an effective therapeutic strategy, in addition to surgical treatment, is essential to mitigate the harmful effects of intestinal ischemia-reperfusion (IIR)-induced tissue injury not only in the intestine itself but also in distant organs, especially the liver. This prompted us to evaluate, for the first time, the role of finerenone (FIN), a non-steroidal selective mineralocorticoid receptor antagonist, and/or roflumilast (ROF), a selective phosphodiesterase 4 inhibitor, in experimentally induced IIR injury in both hepatic and intestinal tissues, with a detailed study of various mechanisms. Materials and Methods: Wistar rats were randomly assigned to 5 groups (N=10): Sham group, IIR group, FIN/ROF, FIN, and ROF-administered groups, with IIR induction. Results: Interestingly, FIN/ROF significantly reduced elevated levels of liver function enzymes, tissue malondialdehyde (MDA), tumor necrosis factor alpha (TNFα), caspase-3 expression, and aldosterone. Furthermore, FIN/ROF could normalize the tissue level of interleukin 10 (IL-10), adenosine monophosphate-activated protein kinase (AMPK), vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), antioxidant parameters, reduced glutathione (GSH), and total antioxidant capacity (TAC) with remarkable improvement in the histopathological features. Conclusion: FIN/ROF could mitigate IIR-induced hepatic and intestinal damage via FIN-mediated blockade of mineralocorticoid receptors and ROF-mediated inhibition of phosphodiesterase 4, and through antioxidant, anti-apoptotic, and anti-inflammatory properties with regulation of the IL-10/AMPK/VEGF/eNOS pathway. Thus, FIN/ROF is a potential medical treatment for IIR, in addition to surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.